Technical Analysis for LGND - Ligand Pharmaceuticals Incorporated

Grade Last Price % Change Price Change
D 124.07 -1.02% -1.28
LGND closed down 3.97 percent on Wednesday, May 12, 2021, on 75 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Up Down Down
Historical LGND trend table...

Date Alert Name Type % Chg
New Downtrend Bearish -1.02%
180 Bearish Setup Bearish Swing Setup -1.02%
Lower Bollinger Band Walk Weakness -1.02%
Inside Day Range Contraction -1.02%
Oversold Stochastic Weakness -1.02%
Bullish Engulfing Bullish -4.95%
Lower Bollinger Band Walk Weakness -4.95%
Multiple of Ten Bullish Other -4.95%
Outside Day Range Expansion -4.95%
Lower Bollinger Band Touch Weakness -4.95%
Older End-of-Day Signals for LGND ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Lower Bollinger Band Support about 1 hour ago
Down 2 % about 2 hours ago
60 Minute Opening Range Breakdown about 4 hours ago
Down 1% about 4 hours ago
Up 1% about 5 hours ago
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Ligand Pharmaceuticals Incorporated Description

Ligand Pharmaceuticals Incorporated, a biotechnology company, engages in the acquisition and development of royalty revenue generating assets in the United States. The company's assets include PROMACTA, an oral thrombopoietin receptor agonist therapy for the treatment of adult patients with chronic immune thrombocytopenic purpura; Kyprolis for the treatment of multiple myeloma; AVINZA, a pain therapeutic; Viviant/Conbriza for the treatment of postmenopausal osteoporosis; Nexterone, an injectable formulation; and Viviant (bazedoxifene) for the treatment of postmenopausal osteoporosis. Its late-stage development programs comprise PROMACTA, which is in is in Phase II clinical studies for the treatment of oncology-related thrombocytopenia in patients with solid tumors, sarcoma, and Myelodysplastic Syndrome. The company's late-stage development programs also include Merck Captisol program that is in Phase III studies; Captisol-enabled Clopidogrel, which is in Phase III studies; RE-021 program, a dual acting receptor antagonist that is in various stages of development for indications of severe kidney diseases; Dinaciclib that is in Phase IIb/III adaptive clinical trials for the treatment of patients with refractory chronic lymphocytic leukemia; and Beta-Secretase Inhibitor, which is in Phase II/III studies for treating Alzheimer's disease. In addition, its late-stage development programs comprise Captisol-enabled Delafloxacin, a Phase III clinical trial product for the management of acute seizure disorder; and Captisol-enabled Delafloxacin that is in Phase III clinical trials for the treatment of acute bacterial skin and skin structure infections. The company has alliances with GlaxoSmithKline, Onyx Pharmaceuticals, Merck, Pfizer, Baxter International, Bristol-Myers Squibb, Celgene, Lundbeck Inc., Eli Lilly and Co., Spectrum Pharmaceuticals, and The Medicines Company. Ligand Pharmaceuticals Incorporated was founded in 1987 and is headquartered in La Jolla, California.


Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Solid Tumors Pain Chemical Compounds Organic Compounds Alzheimer's Disease Kidney Disease Multiple Myeloma Sarcoma Kidney Diseases Myelodysplastic Syndrome Glaxosmithkline Chloroarenes Chronic Lymphocytic Leukemia Lymphocytic Leukemia Clinical Trial Product Osteoporosis Seizure Phenols Carboxylic Acids Thrombocytopenia Skin And Skin Structure Infection Skin And Skin Structure Infections Clopidogrel Immune Thrombocytopenic Purpura Selective Estrogen Receptor Modulators Spectrum Pharmaceuticals

Is LGND a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 219.73
52 Week Low 78.26
Average Volume 176,492
200-Day Moving Average 120.84
50-Day Moving Average 148.19
20-Day Moving Average 141.29
10-Day Moving Average 133.88
Average True Range 6.75
ADX 26.7
+DI 9.91
-DI 31.02
Chandelier Exit (Long, 3 ATRs ) 134.76
Chandelier Exit (Short, 3 ATRs ) 142.24
Upper Bollinger Band 160.14
Lower Bollinger Band 122.43
Percent B (%b) 0.08
BandWidth 26.69
MACD Line -6.39
MACD Signal Line -4.64
MACD Histogram -1.7554
Fundamentals Value
Market Cap 2.02 Billion
Num Shares 16.1 Million
EPS 28.29
Price-to-Earnings (P/E) Ratio 4.43
Price-to-Sales 9.67
Price-to-Book 1.92
PEG Ratio 0.93
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 132.10
Resistance 3 (R3) 132.80 131.26 130.98
Resistance 2 (R2) 131.26 129.54 130.91 130.60
Resistance 1 (R1) 128.30 128.48 127.53 127.60 130.22
Pivot Point 126.76 126.76 126.37 126.41 126.76
Support 1 (S1) 123.80 125.04 123.03 123.10 120.48
Support 2 (S2) 122.26 123.98 121.91 120.10
Support 3 (S3) 119.30 122.26 119.73
Support 4 (S4) 118.60